DFIQ, a Novel Quinoline Derivative, Shows Anticancer Potential by Inducing Apoptosis and Autophagy in NSCLC Cell and In Vivo Zebrafish Xenograft Models.
Huang. Hurng-Wern HW; Bow. Yung-Ding YD; Wang. Chia-Yih CY; Chen. Yen-Chun YC; Fu. Pei-Rong PR; Chang. Kuo-Feng KF; Wang. Tso-Wen TW; Tseng. Chih-Hua CH; Chen. Yeh-Long YL; Chiu. Chien-Chih CC
Key Findings
- DFIQ kills non‑small cell lung cancer cells with IC50 values of 4.16 µM (24 h) and 2.31 µM (48 h).
- The compound triggers apoptosis, DNA damage, and reduces proteins that control the cell cycle.
- DFIQ increases reactive oxygen species, leading to autophagy changes; blocking autophagy with 3‑MA reduces cell death.
Practical Outcomes
- For biohackers, the main takeaway is that DFIQ shows promise as a cancer‑fighting agent in early research, but there are no safe dosage guidelines or human data. It highlights the importance of ROS and autophagy pathways, which could inform future supplement or drug development, but it isn’t something to try now.
Summary
DFIQ is a newly made quinoline chemical that kills lung cancer cells in lab dishes and in tiny fish that carry human tumors. It works by causing the cells to self‑destruct (apoptosis), damaging their DNA, and messing with their waste‑recycling system (autophagy) through a burst of harmful oxygen molecules. The study is still early‑stage and only in animals, so it isn’t ready for people to use yet.
Abstract
Lung cancer is one of the deadliest cancers worldwide due to chemoresistance in patients with late-stage disease. Quinoline derivatives show biological activity against HIV, malaria, bacteriuria, and cancer. DFIQ is a novel synthetic quinoline derivative that induces cell death in both in vitro and in vivo zebrafish xenograft models. DFIQ induced cell death, including apoptosis, and the IC<sub>50</sub> values were 4.16 and 2.31 μM at 24 and 48 h, respectively. DFIQ was also found to induce apoptotic protein cleavage and DNA damage, reduce cell cycle-associated protein expression, and disrupt reactive oxygen species (ROS) reduction, thus resulting in the accumulation of superoxide radicals. Autophagy is also a necessary process associated with chemotherapy-induced cell death. Lysosome accumulation and lysosome-associated membrane protein-2 (LAMP2) depletion were observed after DFIQ treatment, and cell death induction was restored upon treatment with the autophagy inhibitor 3-methyladenine (3-MA). Nevertheless, ROS production was found to be involved in DFIQ-induced autophagy activation and LAMP2 depletion. Our data provide the first evidence for developing DFIQ for clinical usage and show the regulatory mechanism by which DFIQ affects ROS, autophagy, and apoptosis.
Study Information
pubmed
2020
2020-05-25T00:00:00.000Z
10.3390/cancers12051348
18
64